Cadence Pharmaceuticals Comments on USPTO’s Non-Final, Initial Office Action on Reexamination of Patent by longitudeadmin | Aug 15, 2013 | Portfolio News
Corcept Therapeutics announces partnership with Idis for global access to Korlym® by longitudeadmin | Jul 24, 2013 | Portfolio News
The Corus® CAD Gene Expression Test Addresses the Clinical Challenges Associated with the Evaluation of Women Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease by longitudeadmin | Jul 23, 2013 | Portfolio News
Esperion Therapeutics, Inc. Announces Exercise of Underwriters’ Over-Allotment Option for Initial Public Offering by longitudeadmin | Jul 11, 2013 | Portfolio News
Aptus Exceeds 250 Patients in ANCHOR Post-Market Registry by longitudeadmin | Jul 10, 2013 | Portfolio News
